Anmol Nagpal

Takeda partners with Biological E to boost dengue vaccine production in India

Japan's pharma company Takeda partners with Indian vaccine and biologic company Biological E to boost the manufacture of Takeda's dengue vaccine, TAK-003.

Source: PTI representative

The partnership is likely to enhance vaccine manufacturing capabilities, with Biological E scaling up its production capacity to potentially reach 50 million doses annually.

Source: Shutterstock/Representative

This will accelerate Takeda's goal of producing 100 million doses within this decade.

Source: Unsplash

The announcement was made at BioAsia 2024, a regional life science and healthcare forum organised by the Government of Telangana.

Source: Shutterstock

Dengue, the fastest-spreading mosquito-borne viral disease, puts about half of the world's population at risk.

Source: Instagram

This partnership is expected to boost access to the vaccine in dengue-endemic countries, reducing the health impact significantly.

Source: Unsplash

TAK-003 has shown significant protection against dengue in long-term studies and has been approved in over 30 countries.

Source: Unsplash

The partnership aims to further expand this reach, combating unmet public health needs worldwide.

Source: ANI

This announcement aligns with the World Health Organization’s (WHO) goal to achieve zero case-fatality rate due to dengue by the year 2030.

Source: AP / File Photo